SMN-C3 is an orally active SMN2 splicing modulator and has the potential to treat spinal muscular atrophy (SMA). SMN-C3 is in phase I clinical trials co-developed by Roche and PTC Therapeutics for the treatment of spinal muscular atrophy.
武汉永璨生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
武汉永璨生物